All In Biotech

Drug Trial Radar · NCT07665970

SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB41 in Combination With SCTB39G With or Without Standard Therapy in Adult Patients With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jun 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced malignant solid tumors. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

  • SCTB41+SCTB39GDrug

    SCTB41 plus SCTB39G of different doses, IV, every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity(DLT)Time frame: From Day 0 up to Day 21
  2. Objective Response Rate (ORR)Time frame: Up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.